Ligand Pharmaceuticals joins Signet-led financing round in Primrose Bio

PUBT · 1d ago
Ligand Pharmaceuticals joins Signet-led financing round in Primrose Bio
  • Primrose Bio closed a financing round led by new investor Signet Healthcare Partners, with participation from Ligand Pharmaceuticals.
  • Funding aimed at expanding Primrose’s biologics and mRNA manufacturing technology portfolio to support customer programs toward clinical trials.
  • Signet’s James Gale joined Primrose’s board in conjunction with the transaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53410) on September 22, 2026, and is solely responsible for the information contained therein.